5YI.F NYXOAH S.A.
- Market cap
- EUR 77.4M
- P/E
- -
- P/B
- 1.13x
- ROE
- -130.9%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 5YI.F undervalued?
Graham numberThe Graham number of NYXOAH S.A. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
NYXOAH S.A. fundamental analysis
No fundamental analysis for NYXOAH S.A. yet.
NYXOAH S.A. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About NYXOAH S.A.
Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat obstructive sleep apnea. Its lead solution is the Genio system, a hypoglossal neurostimulations therapy for obstructive sleep apnea. The company was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.
Full company profileNYXOAH S.A. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
NYXOAH S.A. annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 852K | 3.08M | 4.35M | 4.52M | 10.0M | 31.0M |
| Gross Profit | 549K | 1.93M | 2.69M | 2.97M | 6.33M | 18.7M |
| Operating Income | -26.2M | -32.5M | -45.1M | -58.8M | -82.9M | -83.9M |
| EBITDA | - | -27.9M | -42.1M | -52.8M | -82.7M | -65.8M |
| Net Income | -27.6M | -31.2M | -43.2M | -59.2M | -90.1M | -89.0M |
| EPS | -1.07 | -1.21 | -1.51 | -1.58 | -2.09 | -0.87 |
| Balance Sheet | ||||||
| Total Assets | 171M | 146M | 124M | 158M | 118M | 149M |
| Total Liabilities | 22.2M | 25.7M | 26.1M | 45.2M | 69.3M | 80.8M |
| Shareholders' Equity | 149M | 120M | 98.0M | 113M | 49.1M | 68.0M |
| Cash & Short-term Investments | 136M | 17.9M | 21.6M | 34.2M | 30.0M | 15.4M |
| Cash Flow | ||||||
| Operating Cash Flow | -25.3M | -28.8M | -44.8M | -49.2M | -69.0M | - |
| Capital Expenditure | 11.8M | 16.3M | 11.0M | 6.07M | 3.77M | 2.89M |
| Free Cash Flow | -37.2M | -45.1M | -55.7M | -55.3M | -72.7M | - |
| Ratios | ||||||
| ROE | -18.6% | -26.0% | -44.1% | -52.3% | -183.4% | -130.9% |
| ROA | -16.2% | -21.4% | -34.8% | -37.4% | -76.0% | -59.8% |
| Net Profit Margin | -3,241.7% | -1,012.5% | -993.8% | -1,310.2% | -899.1% | -287.5% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
NYXOAH S.A. dividends
NYXOAH S.A. has not paid dividends in the last 5 fiscal years.
Who owns NYXOAH S.A.
- Insiders 33.19%
- Institutions 31.09%
- Public & others 35.72%
- Shares outstanding 102M
- Free float 52.6M
NYXOAH S.A. company profile
- Company name
- NYXOAH S.A.
- Ticker
- 5YI.F
- ISIN
- BE0974358906
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 153
- Fiscal year end
- December
- Address
- Rue Edouard Belin 12, Mont-Saint-Guibert, Belgium, 1435
- Phone
- 32 1 045 90 75
- Website
- nyxoah.com
About NYXOAH S.A.
Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat obstructive sleep apnea. Its lead solution is the Genio system, a hypoglossal neurostimulations therapy for obstructive sleep apnea. The company was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.
NYXOAH S.A. management
10- Mr. Robert Taub MBACo-Founder & Chairman · born 1947
- Mr. Bruno OnkelinxChief Technical Officer · born 1972
- Mr. Liam J. KellyChief Executive Officer · born 1967
- Mr. Loic MoreauPresident of International & Interim CFO · born 1980
- Mr. Jeyakumar SubbaroyanChief Science Officer
- Mr. Remi RenardHead of Investor Relations & Corporate Communication
- Ms. An MoonenGeneral Counsel
- Dr. Maurits S. BoonChief Medical Officer
- Mr. Scott HolstineChief Commercial Officer · born 1971
- Ms. Ashlea MittelstaedtChief Strategy Officer